FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease

被引:0
|
作者
Bernstein, Elana J. [1 ]
Boin, Francesco [2 ]
Elicker, Brett [3 ]
Luo, Yiming [1 ]
Ren, Yawen [4 ]
Zhang, Meng [5 ]
Varga, John [6 ]
Assassi, Shervin [5 ]
机构
[1] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, Dept Med,Div Rheumatol, New York, NY USA
[2] Cedars Sinai Med Ctr, Dept Med, Div Rheumatol, Los Angeles, CA USA
[3] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA
[4] Univ Colorado, Dept Med, Div Rheumatol, Denver, CO USA
[5] Univ Texas Hlth Sci Ctr Houston, UTHlth Houston, Dept Med, Div Rheumatol, Houston, TX USA
[6] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
systemic sclerosis; interstitial lung disease; usual interstitial pneumonia; FAM13A; MUC5B; IDIOPATHIC PULMONARY-FIBROSIS; PROMOTER POLYMORPHISM; SUSCEPTIBILITY; GENE; SCLERODERMA; LOCI;
D O I
10.1093/rheumatology/keae573
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The MUC58 promoter single nucleotide polymorphism (SNP) rs35705950 has been associated with idiopathic pulmonary fibrosis (IPF) and RA-related interstitial lung disease (ILD), but not with SSc-ILD. We hypothesized that the MUC58 promoter polymorphism or other IPF susceptibility loci are associated with an increased risk for the uncommon SSc-usual interstitial pneumonia (UIP) endophenotype, rather than SSc-ILD in general. Methods: We performed a cross-sectional study of SSc-ILD patients from four US Scleroderma Programs to investigate the frequency of MUC58 rs35705950 and 12 additional IPF susceptibility loci. SSc-ILD patients were stratified by high resolution chest CT (HRCT) imaging findings into UIP and non-UIP groups. Analysis of HRCTs performed by a thoracic radiologist blinded to participants' characteristics classified each scan as definite UIP, probable UIP, indeterminate or alternative diagnosis, according to American Thoracic Society criteria. Results: Four-hundred and eighty-nine SSc-ILD patients were included; 80% were female and 75% were White. Twenty-three (4.7%) patients had a definite UIP pattern. The MUC58 SNP rs35705950 was not associated with a definite UIP pattern in SSc-ILD. In contrast, patients carrying two copies of the IPF risk gene FAM13A minor allele rs2609255 had significantly higher odds of a definite UIP pattern compared with the other patterns (odds ratio 3.40, 95% CI 1.19-9.70), and compared with an alternative diagnosis (odds ratio 3.65, 95% CI 1.25-10.65). Conclusion: We demonstrated a novel association between FAM13A and SSc-UIP. Contrary to IPF and RA-ILD, the MUC58 promoter polymorphism was not associated with a definite UIP pattern in SSc-ILD.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Koutroumpas, Athanasios
    Ziogas, Athanasios
    Alexiou, Ioannis
    Barouta, Georgia
    Sakkas, Lazaros I.
    CLINICAL RHEUMATOLOGY, 2010, 29 (10) : 1167 - 1168
  • [22] Responses to exercise in systemic sclerosis-associated interstitial lung disease
    Donnelly, Ronan P.
    Smyth, Anita E.
    Mullan, Charles
    Riley, Marshall S.
    Nicholls, D. Paul
    CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, 2023, 43 (04) : 253 - 262
  • [23] Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
    Yamasaki, Yoshioki
    Kuwana, Masataka
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (06) : 547 - 560
  • [24] Systemic sclerosis-associated interstitial lung disease treated with tocilizumab
    Dauny, Vincent
    Borie, Raphael
    Forien, Marine
    Ghanem, Mada
    Palazzo, Elisabeth
    Jelin, Germain
    Dieude, Philippe
    Ottaviani, Sebastien
    INTERNAL MEDICINE JOURNAL, 2021, 51 (06) : 999 - 1000
  • [25] Molecular Insights Into Systemic Sclerosis-Associated Interstitial Lung Disease
    Silver, Richard M.
    Feghali-Bostwick, Carol A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 (03) : 485 - 487
  • [26] Pleuroparenchymal fibroelastosis in systemic sclerosis-associated interstitial lung disease
    Sari, Alper
    Onder, Omer
    Armagan, Berkan
    Bolek, Ertugrul Cagri
    Farisogullari, Bayram
    Bilgin, Emre
    Yardimci, Gozde Kubra
    Ariyurek, Macit
    Akdogan, Ali
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (01) : 83 - 88
  • [27] Current treatment of systemic sclerosis-associated interstitial lung disease
    Bes, Cemal
    Cetinkaya, Erdogan
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2022, 70 (01): : 85 - 92
  • [28] Tomographic Fibrosis Score in the Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
    Ozmen, Mustafa
    Gumus, Cesur
    Otman, Eda
    Sinci, Kazim Ayberk
    Aysin, Idil Kurut
    Solmaz, Dilek
    Akar, Servet
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2023, 10 (03) : 107 - 113
  • [29] Therapeutic effects of thalidomide on patients with systemic sclerosis-associated interstitial lung disease
    Pan, Jie
    Dong, Fei
    Ma, Li
    Zhao, Cheng
    Qin, Fang
    Wen, Jing
    Wei, Wanling
    Lei, Ling
    JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2023, 8 (03) : 231 - 240
  • [30] Frailty Is Common And Associated With Dyspnea Severity In Patients With Systemic Sclerosis-Associated Interstitial Lung Disease
    Winstone, T. A.
    Kwan, J. M.
    Milne, K. M.
    Schooley, F.
    Dunne, J.
    Wilcox, P. G.
    Ryerson, C. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193